Related references
Note: Only part of the references are listed.Precision Medicine - Personalized, Problematic, and Promising
J. Larry Jameson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
VALUE-BASED DIFFERENTIAL PRICING: EFFICIENT PRICES FOR DRUGS IN A GLOBAL CONTEXT
Patricia Danzon et al.
HEALTH ECONOMICS (2015)
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2014)
Intellectual Property and Regulation of Molecular Pathology Tests
Roger D. Klein
CANCER JOURNAL (2014)
PATENT WATCH Australian court upholds Myriad's gene patent
Charlotte Harrison
NATURE REVIEWS DRUG DISCOVERY (2014)
Molecular profiling and companion diagnostics: where is personalized medicine in cancer heading?
Mukesh Verma
PERSONALIZED MEDICINE (2014)
Are Companion Diagnostics Useful?
J. Carl Barrett et al.
CLINICAL CHEMISTRY (2013)
Integrating Companion Diagnostic Assays into Drug Development: Addressing the Challenges from the Diagnostic Perspective
John Beeler
DRUG DEVELOPMENT RESEARCH (2013)
Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview
Yao-Shan Fan
GENETIC TESTING AND MOLECULAR BIOMARKERS (2013)
Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical Oncology
Kenneth Offit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
An economic model to value companion diagnostics in non-small-cell lung cancer
Robert D. Lieberthal et al.
PERSONALIZED MEDICINE (2013)
Can and should value-based pricing be applied to molecular diagnostics?
Martina Garau et al.
PERSONALIZED MEDICINE (2013)
Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness A Systematic Review
Martin Frank et al.
PHARMACOECONOMICS (2013)
Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
Adrian Towse et al.
VALUE IN HEALTH (2013)
PRICING OF MEDICAL DEVICES UNDER COVERAGE UNCERTAINTY-A MODELLING APPROACH
Alan J. Girling et al.
HEALTH ECONOMICS (2012)
Paying for personalized care: Cancer biomarkers and comparative effectiveness
Rahber Thariani et al.
MOLECULAR ONCOLOGY (2012)
Do companion diagnostics make economic sense for drug developers?
Amit Agarwal
NEW BIOTECHNOLOGY (2012)
Challenges in the Development and Reimbursement of Personalized Medicine-Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
Eric Faulkner et al.
VALUE IN HEALTH (2012)
Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
Edward D. Blair et al.
JOURNAL OF PERSONALIZED MEDICINE (2012)
How Comparative Effectiveness Research Can Help Advance 'Personalized Medicine' In Cancer Treatment
Scott D. Ramsey et al.
HEALTH AFFAIRS (2011)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Linking pharmacogenetics-based diagnostics and drugs for personalized medicine
Louis P. Garrison et al.
HEALTH AFFAIRS (2006)
A systematic review of cost-effectiveness analyses of pharmacogenomic interventions
KA Phillips et al.
PHARMACOGENOMICS (2004)
The economics of gene therapy and of pharmacogenetics
P Danzon et al.
VALUE IN HEALTH (2002)
Share Paper
